Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 2
1997 2
2009 1
2012 1
2013 6
2014 2
2015 4
2016 5
2017 3
2018 5
2019 7
2020 7
2021 12
2022 4
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Champiat S, et al. Among authors: barreau e. Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Ann Oncol. 2016. PMID: 26715621 Free article. Review.
Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L; FIREFISH Working Group. Baranello G, et al. N Engl J Med. 2021 Mar 11;384(10):915-923. doi: 10.1056/NEJMoa2009965. Epub 2021 Feb 24. N Engl J Med. 2021. PMID: 33626251 Clinical Trial.
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L; FIREFISH Working Group. Darras BT, et al. N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047. N Engl J Med. 2021. PMID: 34320287
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Servais L, Xiong H, Zanoteli E, Baranello G, Bruno C, Day JW, Deconinck N, Klein A, Mercuri E, Vlodavets D, Wang Y, Dodman A, El-Khairi M, Gorni K, Jaber B, Kletzl H, Gaki E, Fontoura P, Darras BT; FIREFISH Study Group. Masson R, et al. Lancet Neurol. 2022 Dec;21(12):1110-1119. doi: 10.1016/S1474-4422(22)00339-8. Epub 2022 Oct 14. Lancet Neurol. 2022. PMID: 36244364 Clinical Trial.
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Staunton H, Yeung WY, Martin C, Fontoura P, Day JW; SUNFISH Study Group. Mercuri E, et al. Lancet Neurol. 2022 Jan;21(1):42-52. doi: 10.1016/S1474-4422(21)00367-7. Lancet Neurol. 2022. PMID: 34942136
Bilateral uveitis associated with nivolumab therapy.
Rémond AL, Barreau E, Le Hoang P, Bodaghi B. Rémond AL, et al. Among authors: barreau e. J Fr Ophtalmol. 2018 Mar;41(3):e91-e94. doi: 10.1016/j.jfo.2018.02.001. Epub 2018 Mar 21. J Fr Ophtalmol. 2018. PMID: 29573860 French.
[Retinal arterial macroaneurysm on OCT angiography].
Tibi K, Riou B, Barreau E, Labétoulle M, Rousseau A. Tibi K, et al. Among authors: barreau e. J Fr Ophtalmol. 2022 Feb;45(2):251-252. doi: 10.1016/j.jfo.2021.08.028. Epub 2022 Jan 6. J Fr Ophtalmol. 2022. PMID: 35000799 French. No abstract available.
Ocular surface toxicities associated with modern anticancer therapies.
Boucher R, Haigh O, Barreau E, Champiat S, Lambotte O, Adam C, Labetoulle M, Rousseau A. Boucher R, et al. Among authors: barreau e. Surv Ophthalmol. 2024 Mar-Apr;69(2):198-210. doi: 10.1016/j.survophthal.2023.10.002. Epub 2023 Oct 6. Surv Ophthalmol. 2024. PMID: 37806566 Review.
Refractive changes during immunotherapy: Think diabetes!
Benassaia E, Riveline JP, Routier E, Barreau E, Robert C. Benassaia E, et al. Among authors: barreau e. Eur J Cancer. 2021 Oct 8;158:15-16. doi: 10.1016/j.ejca.2021.07.047. Online ahead of print. Eur J Cancer. 2021. PMID: 34634540 No abstract available.
Punctal and canalicular plugs: Indications, efficacy and safety.
Best AL, Labetoulle M, Legrand M, M'garrech M, Barreau E, Rousseau A. Best AL, et al. Among authors: barreau e. J Fr Ophtalmol. 2019 Mar;42(3):e95-e104. doi: 10.1016/j.jfo.2018.12.003. Epub 2019 Jan 26. J Fr Ophtalmol. 2019. PMID: 30692031 Review.
62 results